Overview
CNS Drugs provides researchers and healthcare professionals with essential information on the most important aspects of drug therapies used for the management of neurological and psychiatric disorders.
Via a program of reviews and original research articles, the journal addresses major issues relating to drug therapy of these disorders, including the pharmacology, efficacy and adverse effects of the major classes of drugs; information on newly developed drugs and drug classes; the therapeutic implications of latest research into the aetiology of neurological and psychiatric disorders; and the practical management of specific clinical situations.
As a hybrid journal, CNS Drugs does not charge authors to publish using the traditional subscription-based publishing route, but does offer the option to publish accepted articles open access if authors so wish or if their funders require (more information).
CNS Drugs offers a range of additional features designed to increase the visibility, readership and educational value of the journal’s content (more information).
- Editor
-
- Susan Pochon
- Impact factor
- 6.0 (2022)
- 5 year impact factor
- 6.2 (2022)
- Submission to first decision (median)
- 8 days
- Downloads
- 812,876 (2023)
Latest articles
Journal updates
-
Digital Features
CNS Drugs is able to host a range of digital features, with a number of options available to authors.
Journal information
- Electronic ISSN
- 1179-1934
- Print ISSN
- 1172-7047
- Abstracted and indexed in
-
- ANVUR
- BFI List
- BIOSIS
- Baidu
- CLOCKSS
- CNKI
- CNPIEC
- Chemical Abstracts Service (CAS)
- Current Contents/Clinical Medicine
- Current Contents/Life Sciences
- Dimensions
- EBSCO
- EMBASE
- Google Scholar
- Japanese Science and Technology Agency (JST)
- Medline
- Naver
- OCLC WorldCat Discovery Service
- Pathway Studio
- Portico
- ProQuest
- PsycINFO
- Reaxys
- SCImago
- SCOPUS
- Science Citation Index Expanded (SCIE)
- Semantic Scholar
- TD Net Discovery Service
- UGC-CARE List (India)
- Wanfang
- Copyright information